Aptevo Therapeutics Inc. (APVO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aptevo Therapeutics Inc. (APVO) closed at USD 1.73 on 2026-10-14, a change of -93.4 % over the past year, with a market capitalization of USD 3.08M.

Aptevo Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aptevo Therapeutics Inc. key figures

Previous close

USD 1.73 (2026-10-14)

1-year change

-93.4 %

Market cap

USD 3.08M

Enterprise value

USD -2.52M

P/E ratio (trailing)

0.03

P/E ratio (forward)

-0.16

EPS (trailing)

66.96

EPS (forward)

-10.40

PEG ratio

n/a

Price to book

0.40

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.62

Employees

33

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aptevo Therapeutics Inc. and compare it with other stocks.